Mersana Therapeutics

Summary

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

History

Mersana Therapeutics was founded in Cambridge, Massachusetts in 2011 and is a clinical-stage biopharmaceutical company dedicated to transforming the lives of cancer patients through its differentiated, in-house designed ADC platform, Fleximer. It has raised $347 million in Series C funding in June 2020 and is developing antibody-drug conjugate therapies for solid tumors and hematologic malignancies.

Mission

To deliver innovative, safe and effective antibody drug conjugate therapies for the benefit of cancer patients worldwide.

Vision

To be at the forefront of the next generation of innovative cancer therapies.

References

https://in.investing.com/equities/mersana-therapeutics-inc

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/mersana-therapeutics

https://finance.yahoo.com/quote/MRSN/

https://www.mersana.com

https://sec.report/CIK/0001442836

Contacts

Follow Us

Mersana Therapeutics

Share

Contacts

Follow Us